Zhejiang HisunPharma will provide clinical trial supplies of a novel inhaled treatment for drug resistant TB for Seattle’s IDRI (Infectious Disease Research Institute). The agreement, described as a partnership, will presumably include commercial supply, though details were not disclosed. CPZEN-45 was originally discovered by the Institute of Microbial Chemistry (IMC), a nonprofit Tokyo research institute. It has reached late pre-clinical development through work done at the IDRI and the Lilly TB Drug Discovery Initiative, which is focused on finding effective treatments for drug-resistant TB.
Source: ChinaBio Today
